Dr. Jennifer Doudna won the Nobel Prize for pioneering gene-editing technology CRISPR. Today, Scribe Therapeutics, the company she co-founded, just raised $128.7 million in its IPO for a much bigger ambition: using CRISPR to prevent heart disease. Scribe Therapeutics co-founder and Scientific Advisor Jennifer Doudna joins Ed Ludlow on “Bloomberg Tech” from the Nasdaq.
——–
Like this video? Subscribe to Bloomberg Technology on YouTube:
Watch the latest full episodes of “Bloomberg Technology” with Caroline Hyde and Ed Ludlow here:
Get the latest in tech from Silicon Valley and around the world here:
Connect with us on…
X:
Facebook:
Instagram:
Follow Ed Ludlow on X here:
Follow Caroline Hyde on X here:
Listen to the daily Bloomberg Technology podcast here:
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:
source
